Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Antibodies to intracellular cancer antigens combined with chemotherapy enhance anti-cancer immunity

Pre-clinical study shows delay in tumor growth and prolonged survival time

An international team of scientists in Japan, Switzerland, and the United States has confirmed that combining chemotherapy and immunotherapy in cancer treatment enhances the immune system's ability to find and eliminate cancer cells, even when the cancer-associated proteins targeted by the immune system are hidden behind the cancer cell membrane.

In a study published in Cancer Research by Noguchi et al., the scientists show that antibodies, which have been successful in treating certain types of cancers, can effectively reach elusive intracellular targets, delaying tumor growth and prolonging survival when combined with chemotherapy.

"The study provides proof-of-principle for a powerful new strategy that may greatly expand the arsenal of potential targets for cancer drug development and that could be broadly applicable to many different cancer types," said Hiroyoshi Nishikawa, M.D., Ph.D., a Cancer Research Institute (CRI)-funded associate professor in the Department of Experimental Immunology at the Immunology Frontier Research Center, Osaka University, and a senior author on the paper.

The introduction of antibodies against cancer represents one of the biggest successes of cancer therapy over the past 20 years. These treatments work by targeting markers on the surface of cancer cells, and include the blockbuster therapies Herceptin, which targets the HER2/neu marker on breast cancer cells, and Rituxan, which targets the CD20 marker on B cell lymphoma.

The majority of markers that can distinguish cancer cells from normal cells, however, are found exclusively inside cancer cells, where antibodies typically cannot access them. "Therapies that can successfully target cancer antigens found within cancer cells may be able to fight cancer without causing unwanted side effects due to collateral damage to healthy cells," said study co-lead author Gerd Ritter, Ph.D., associate director of the New York Branch of the Ludwig Institute for Cancer Research (LICR), and a leading member of the CRI/LICR Cancer Vaccine Collaborative, which also supported the study.

To assess whether antibody treatment against an intracellular antigen might be successful, the researchers used an antibody against the prototypic cancer antigen NY-ESO-1 and tested it in a model of colon cancer engineered to express NY-ESO-1 within its cancer cells. Alone, the antibody had no effect against the cancer. By using chemotherapy to release NY-ESO-1 from the cancer cells prior to the administration of the antibody, however, they were able to significantly delay cancer progression and prolong survival. The researchers then tested the strategy in another cancer model using a different type of chemotherapy and showed similar results, demonstrating that this approach could be applicable to different tumor types using various standard chemotherapies.

By monitoring the immune responses to these treatments, the researchers on the study found that the anti-tumor effect of the combination was dependent on CD8+, or killer, T cells. Rather than working to kill the cancer cells directly, the antibody worked by binding to the NY-ESO-1 antigen and facilitating its presentation to CD8+ T cells, which then exerted the anti-tumor effects. These findings not only have implications for how scientists understand the mechanisms of current antibody treatments for cancer, but they also shed light on a fundamental question in clinical cancer immunology, which asks how people develop spontaneous antibody and/or CD8+ T cell responses against NY-ESO-1.

"These studies are also representative of a growing trend in immunotherapy treatment, namely the use of chemotherapy and other standard therapies to augment anti-tumor immunity," stated Hiroshi Shiku, M.D., chairman and professor in the Department of Medical Oncology and Immunology, Mie University Graduate School of Medicine, Japan, and a lead investigator on the study. Until very recently, it was thought that these treatments served to uniformly dampen the immune system and would therefore limit the potential efficacy of immunotherapies used in tandem or in sequence. A growing body of literature, however, is suggesting that certain cytotoxic, or "cell-killing," therapies such as chemotherapy and radiation, used in strategic ways, can synergize with immunotherapies to strengthen or expand the anti-tumor immune response.

Based on the success of their preclinical investigations, the study researchers are eager to take the approach into clinical testing. Such a trial would bridge what immunologists refer to as passive immunotherapy and active immunotherapy.

"It's passive because we're using antibodies manufactured outside the body—the body doesn't have to do the work to make these antibodies; but it's also active because these antibodies then mobilize the immune system to actively begin producing potent cells and endogenous molecules like cytokines and complement to attack the tumor. It's a powerful strategy that for the first time capitalizes on the full therapeutic potential of antibodies as mediators of tumor elimination," Ritter said.

Publication Reference: Noguchi et al. Intracellular tumor-associated antigens represent effective targets for passive immunotherapy. Cancer Res. canres.3072.2011; Published OnlineFirst February 8, 2012;

About the Cancer Research Institute

The Cancer Research Institute, a nonprofit established in 1953, is the global leader in cancer immunology. Since its inception, CRI has invested hundreds of millions of dollars to support research conducted by more than 3,000 scientists and clinicians worldwide to understand the immune system and how it can be harnessed to conquer all cancers. This work has laid the foundation for nearly every major cancer immunotherapy breakthrough over the past half century. Guided by an international panel of the world's leading immunologists and cancer immunologists, including three Nobel laureates and 29 members of the U.S. National Academy of Sciences, CRI provides essential funding to support every stage of discovery, from laboratory investigation to clinical trials of the most promising cancer immunotherapies for patients. CRI also sponsors a seminal international symposium on cancer immunology each year, hosts annual colloquia dedicated to overcoming challenges in immunotherapy research and development, forges collaborative partnerships between academia and industry to facilitate the development pathway for novel immunotherapeutics, and presents special recognition awards to individuals who have made outstanding contributions to cancer research, patient care, and public awareness. Through its sustaining support and leadership in the field, CRI is accelerating the development of better, safer, and more effective immunotherapies that stand to revolutionize the treatment of all cancers. For more information, visit
About The Ludwig Institute for Cancer Research

LICR is an international non-profit organization committed to improving the understanding and control of cancer through integrated laboratory and clinical discovery. Leveraging its worldwide network of investigators and the ability to sponsor and conduct its own clinical trials, the Institute is actively engaged in translating its discoveries into applications for patient benefit. Since its establishment in 1971, the Institute has expended more than $1.5 billion on cancer research.
About the Cancer Vaccine Collaborative

The Cancer Vaccine Collaborative (CVC), a joint program of the Cancer Research Institute (CRI) and the Ludwig Institute for Cancer Research Ltd (LICR), is a coordinated global network of clinical trial sites, with special expertise in immunology, conducting parallel early stage clinical trials to identify the optimal composition of successful therapeutic cancer vaccines. CVC investigators are supported by a comprehensive independent trials management infrastructure that provides regulatory, safety, and compliance expertise and oversight, trial management, shared data collection software, intellectual property management, and funding. Since the program's inception in 2001, the Collaborative has completed or is currently conducting more than 45 early phase clinical trials of therapeutic cancer vaccines. For more information, go to

Rachel Steinhardt | EurekAlert!
Further information:

More articles from Health and Medicine:

nachricht Advanced analysis of brain structure shape may track progression to Alzheimer's disease
26.10.2016 | Massachusetts General Hospital

nachricht Indian roadside refuse fires produce toxic rainbow
26.10.2016 | Duke University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Etching Microstructures with Lasers

Ultrafast lasers have introduced new possibilities in engraving ultrafine structures, and scientists are now also investigating how to use them to etch microstructures into thin glass. There are possible applications in analytics (lab on a chip) and especially in electronics and the consumer sector, where great interest has been shown.

This new method was born of a surprising phenomenon: irradiating glass in a particular way with an ultrafast laser has the effect of making the glass up to a...

Im Focus: Light-driven atomic rotations excite magnetic waves

Terahertz excitation of selected crystal vibrations leads to an effective magnetic field that drives coherent spin motion

Controlling functional properties by light is one of the grand goals in modern condensed matter physics and materials science. A new study now demonstrates how...

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

How nanoscience will improve our health and lives in the coming years

27.10.2016 | Materials Sciences

OU-led team discovers rare, newborn tri-star system using ALMA

27.10.2016 | Physics and Astronomy

'Neighbor maps' reveal the genome's 3-D shape

27.10.2016 | Life Sciences

More VideoLinks >>>